Investigation of thrombin concentration at the time of clot formation in simultaneous thrombin and fibrin generation assays.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
received:
18
07
2023
accepted:
16
11
2023
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
22
4
2024
Statut:
epublish
Résumé
Thrombin generation (TG) and fibrin clot formation represent the central process of blood coagulation. Up to 95% of thrombin is considered to be generated after the clot is formed. However, this was not investigated in depth. In this study, we conducted a quantitative analysis of the Thrombin at Clot Time (TCT) parameter in 5758 simultaneously recorded TG and clot formation assays using frozen plasma samples from commercial sources under various conditions of activation. These samples were supplemented with clotting factor concentrates, procoagulant lipid vesicles and a fluorogenic substrate and triggered with tissue factor (TF). We found that TCT is often close to a 10% of thrombin peak height (TPH) yet it can be larger or smaller depending on whether the sample has low or high TPH value. In general, the samples with high TPH are associated with elevated TCT. TCT appeared more sensitive to some procoagulant phenotypes than other commonly used parameters such as clotting time, TPH or Thrombin Production Rate (TPR). In a minority of cases, TCT were not predicted from TG parameters. For example, elevated TCT (above 15% of TPH) was associated with either very low or very high TPR values. We conclude that clotting and TG assays may provide complementary information about the plasma sample, and that the TCT parameter may serve as an additional marker for the procoagulant potential in plasma sample.
Identifiants
pubmed: 38649717
doi: 10.1038/s41598-023-47694-5
pii: 10.1038/s41598-023-47694-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9225Informations de copyright
© 2024. The Author(s).
Références
Narayanan, S. Preanalytical aspects of coagulation testing. Haematologica 80, 1–6 (1995).
pubmed: 7628761
Othman, M. & Kaur, H. Thromboelastography (TEG). Methods Mol. Biol. 1646, 533–543. https://doi.org/10.1007/978-1-4939-7196-1_39 (2017).
doi: 10.1007/978-1-4939-7196-1_39
pubmed: 28804853
Sakai, T. Comparison between thromboelastography and thromboelastometry. Minerva. Anestesiol. 85, 1346–1356 (2019).
doi: 10.23736/S0375-9393.19.13687-5
pubmed: 31630507
Negrier, C., Shima, M. & Hoffman, M. The central role of thrombin in bleeding disorders. Blood Rev 38, 100582. https://doi.org/10.1016/j.blre.2019.05.006 (2019).
doi: 10.1016/j.blre.2019.05.006
pubmed: 31164248
Tripodi, A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 62, 699–707. https://doi.org/10.1373/clinchem.2015.248625 (2016).
doi: 10.1373/clinchem.2015.248625
pubmed: 26955824
Kintigh, J., Monagle, P. & Ignjatovic, V. A review of commercially available thrombin generation assays. Res. Pract. Thromb. Haemost. 2, 42–48. https://doi.org/10.1002/rth2.12048 (2018).
doi: 10.1002/rth2.12048
pubmed: 30046705
Hemker, H. C. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. 33, 4–15. https://doi.org/10.1159/000071636 (2003).
doi: 10.1159/000071636
pubmed: 12853707
Al Dieri, R., De-Laat, B. & Hemker, H. C. Thrombin generation what have we learned?. Blood Rev. 26, 197–203. https://doi.org/10.1016/j.blre.2012.06.001 (2012).
doi: 10.1016/j.blre.2012.06.001
pubmed: 22762893
Nagashima, H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J. Biol. Chem. 277, 50439–50444. https://doi.org/10.1074/jbc.M208222200 (2002).
doi: 10.1074/jbc.M208222200
pubmed: 12496240
Xin, K. Z., Chang, W. C. & Ovanesov, M. V. Interconnectedness of global hemostasis assay parameters in simultaneously evaluated thrombin generation, fibrin generation and clot lysis in normal plasma. Thromb. Res. 140, 132–139. https://doi.org/10.1016/j.thromres.2015.11.023 (2016).
doi: 10.1016/j.thromres.2015.11.023
pubmed: 26632515
Menis, M. et al. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008–2011. Am. J. Hematol. 88, 1035–1040. https://doi.org/10.1002/ajh.23559 (2013).
doi: 10.1002/ajh.23559
pubmed: 23907744
Ekezue, B. F. et al. Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during 2008–2013. J. Thromb. Haemost. 13, 2168–2179. https://doi.org/10.1111/jth.13155 (2015).
doi: 10.1111/jth.13155
pubmed: 26414338
Miszta, A. et al. A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice. Blood 135, 1704–1717. https://doi.org/10.1182/blood.2019004267 (2020).
doi: 10.1182/blood.2019004267
pubmed: 32315384
pmcid: 7205812
Bouck, E. G. et al. COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. Arterioscler. Thromb. Vasc. Biol. 41, 401–414. https://doi.org/10.1161/ATVBAHA.120.315338 (2021).
doi: 10.1161/ATVBAHA.120.315338
pubmed: 33196292
Hathcock, J. J. & Nemerson, Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa. Blood 104, 123–127. https://doi.org/10.1182/blood-2003-12-4352 (2004).
doi: 10.1182/blood-2003-12-4352
pubmed: 15016647
Fredenburgh, J. C., Stafford, A. R., Pospisil, C. H. & Weitz, J. I. Modes and consequences of thrombin’s interaction with fibrin. Biophys. Chem. 112, 277–284. https://doi.org/10.1016/j.bpc.2004.07.031 (2004).
doi: 10.1016/j.bpc.2004.07.031
pubmed: 15572259
de Bosch, N. B., Mosesson, M. W., Ruiz-Saez, A., Echenagucia, M. & Rodriguez-Lemoin, A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb. Haemost. 88, 253–258 (2002).
doi: 10.1055/s-0037-1613195
pubmed: 12195697
Mosesson, M. W. & Antithrombin, I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb. Haemost. 89, 9–12 (2003).
doi: 10.1055/s-0037-1613536
pubmed: 12540947
Pitkanen, H. et al. Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma. Thromb. Res. 135, 167–174. https://doi.org/10.1016/j.thromres.2014.10.020 (2015).
doi: 10.1016/j.thromres.2014.10.020
pubmed: 25466844
Dashkevich, N. M. et al. Thrombin activity propagates in space during blood coagulation as an excitation wave. Biophys. J. 103, 2233–2240. https://doi.org/10.1016/j.bpj.2012.10.011 (2012).
doi: 10.1016/j.bpj.2012.10.011
pubmed: 23200057
pmcid: 3512051
Panteleev, M. A. et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys. J. 90, 1489–1500. https://doi.org/10.1529/biophysj.105.069062 (2006).
doi: 10.1529/biophysj.105.069062
pubmed: 16326897
Wolberg, A. S. & Campbell, R. A. Thrombin generation, fibrin clot formation and hemostasis. Transfus. Apher. Sci. 38, 15–23. https://doi.org/10.1016/j.transci.2007.12.005 (2008).
doi: 10.1016/j.transci.2007.12.005
pubmed: 18282807
pmcid: 2408736
Weisel, J. W. & Nagaswami, C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys. J. 63, 111–128. https://doi.org/10.1016/S0006-3495(92)81594-1 (1992).
doi: 10.1016/S0006-3495(92)81594-1
pubmed: 1420861
pmcid: 1262129
Ryan, E. A., Mockros, L. F., Weisel, J. W. & Lorand, L. Structural origins of fibrin clot rheology. Biophys. J. 77, 2813–2826. https://doi.org/10.1016/S0006-3495(99)77113-4 (1999).
doi: 10.1016/S0006-3495(99)77113-4
pubmed: 10545379
pmcid: 1300553
Kaibara, M. & Fukada, E. The influence of the concentration of thrombin on the dynamic viscoelasticity of clotting blood and fibrinogen-thrombin systems. Biorheology 8, 139–147. https://doi.org/10.3233/bir-1971-83-404 (1971).
doi: 10.3233/bir-1971-83-404
pubmed: 5169566
Mann, K. G., Brummel, K. & Butenas, S. What is all that thrombin for?. J. Thromb. Haemost. 1, 1504–1514. https://doi.org/10.1046/j.1538-7836.2003.00298.x (2003).
doi: 10.1046/j.1538-7836.2003.00298.x
pubmed: 12871286
Hemker, H. C. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol. Haemost. Thromb. 32, 249–253. https://doi.org/10.1159/000073575 (2002).
doi: 10.1159/000073575
pubmed: 13679651
Jankowski, W. et al. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. Blood Adv. 3, 2668–2678. https://doi.org/10.1182/bloodadvances.2019000338 (2019).
doi: 10.1182/bloodadvances.2019000338
pubmed: 31506285
pmcid: 6737420
Sridhar, G. et al. Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. Transfusion 54, 2553–2565. https://doi.org/10.1111/trf.12663 (2014).
doi: 10.1111/trf.12663
pubmed: 24804899
Parunov, L. A., Surov, S. S., Liang, Y., Lee, T. K. & Ovanesov, M. V. Can the diagnostic reliability of the thrombin generation test as a global haemostasis assay be improved? The impact of calcium chloride concentration. Haemophilia 23, 466–475. https://doi.org/10.1111/hae.13174 (2017).
doi: 10.1111/hae.13174
pubmed: 28205396
Franchini, M. & Mannucci, P. M. Modifiers of clinical phenotype in severe congenital hemophilia. Thromb. Res. 156, 60–64. https://doi.org/10.1016/j.thromres.2017.05.038 (2017).
doi: 10.1016/j.thromres.2017.05.038
pubmed: 28599169
Dolan, G. et al. Haemophilia B: Where are we now and what does the future hold?. Blood Rev. 32, 52–60. https://doi.org/10.1016/j.blre.2017.08.007 (2018).
doi: 10.1016/j.blre.2017.08.007
pubmed: 28826659
Hedner, U. NovoSeven as a universal haemostatic agent. Blood Coagul. Fibrinolysis. 11(Suppl 1), S107-111. https://doi.org/10.1097/00001721-200004001-00020 (2000).
doi: 10.1097/00001721-200004001-00020
pubmed: 10850574
Allen, G. A. et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler. Thromb. Vasc. Biol. 27, 683–689. https://doi.org/10.1161/01.ATV.0000257204.82396.2b (2007).
doi: 10.1161/01.ATV.0000257204.82396.2b
pubmed: 17204663
Gidley, G. N. et al. Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency. Blood Adv. 2, 1076–1088. https://doi.org/10.1182/bloodadvances.2017015123 (2018).
doi: 10.1182/bloodadvances.2017015123
pubmed: 29760205
pmcid: 5965046
Tarandovskiy, I. D., Rajabi, A. A., Karnaukhova, E. & Buehler, P. W. Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin. J. Thromb. Thrombol. 48, 81–87. https://doi.org/10.1007/s11239-019-01869-y (2019).
doi: 10.1007/s11239-019-01869-y
Tarandovskiy, I. D., Shin, H. K. H., Baek, J. H., Karnaukhova, E. & Buehler, P. W. Interspecies comparison of simultaneous thrombin and plasmin generation. Sci. Rep. 10, 3885. https://doi.org/10.1038/s41598-020-60436-1 (2020).
doi: 10.1038/s41598-020-60436-1
pubmed: 32127577
pmcid: 7054422
van Geffen, M. et al. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin. Exp. Immunol. 167, 472–478. https://doi.org/10.1111/j.1365-2249.2011.04541.x (2012).
doi: 10.1111/j.1365-2249.2011.04541.x
pubmed: 22288590
pmcid: 3374279
van Geffen, M. et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology 16, 327–336. https://doi.org/10.1179/102453311X13085644680348 (2011).
doi: 10.1179/102453311X13085644680348
pubmed: 22183066
Matsumoto, T., Nogami, K. & Shima, M. Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb. Haemost. 110, 761–768. https://doi.org/10.1160/TH13-04-0345 (2013).
doi: 10.1160/TH13-04-0345
pubmed: 24072166